About this trial
The primary outcome of this study is to evaluate changes in cardiovascular risk after endoscopic sleeve gastroplasty (ESG) in patients at high cardiovascular risk, using the SCORE2 ( Systematic COronary Risk Evaluation 2) and SCORE2-OP ( Systematic COronary Risk Evaluation 2 Older Persons) risk scores, which estimate the risk of having a cardiovascular event.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
informed consent
obesity or overweight
atherosclerotic cardiovascular disease
type 1 or type 2 diabetes mellitus
Disqualifiers
chronic inflammatory diseases
active viral or bacterial infections
severe anaemia or severe coagulopathy
severe chronic kidney failure
Trial design
Single group
Treatments tested in this trial
echocardiography
Other interventionEchocardiography will be performed in each patient The following parameters will be assessed: systolic function, diastolic function, presence/absence of ventricular hypertrophy, left atrial volume indexed (LAVi), left atrial strain (LAS), valvular morphology and function, estimated intracardiac pressures
Coronary CT angiography
RadiationCoronary CT angiography has a duration of 10-15 minutes per patient and requires the use of contrast
blood analysis
Biological/VaccineBlood count, liver and kidney function, coagulation assessment, C-reactive protein, glycaemic and lipidic profile
Treatment groups
Trial outcomes
Primary outcomes
Changes in Systematic Coronary Risk Evaluation 2 ( SCORE 2) and Systematic Coronary Risk Evaluation 2 Older Persons (SCORE 2 OP) using algorithms after endoscopic sleeve gastroplasty.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: